Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Brilinta is a prescription antiplatelet medicine containing ticagrelor. It reduces cardiovascular death, heart attack, and stroke risk in selected patients with acute coronary syndrome or prior heart attack. It also has indications for selected high-risk coronary artery disease and for reducing stroke risk after mild acute ischemic stroke or high-risk transient ischemic attack.
read more about brilinta ...Ticagrelor and its active metabolite reversibly bind the platelet P2Y12 ADP receptor. This blocks ADP-mediated signaling and reduces platelet activation and aggregation. The antiplatelet effect lowers formation of arterial blood clots but also raises bleeding risk.
Brilinta is used after acute coronary syndrome or a prior heart attack to reduce cardiovascular death, heart attack, and stroke. It also reduces first heart attack or stroke risk in selected people with high-risk coronary artery disease and reduces stroke risk after mild acute ischemic stroke or high-risk transient ischemic attack.
Acute coronary syndrome or prior heart attack treatment starts with a 180 mg loading dose, followed by 90 mg twice daily during the first year and 60 mg twice daily after one year. High-risk coronary artery disease uses 60 mg twice daily. Mild acute ischemic stroke or high-risk transient ischemic attack uses 180 mg once, then 90 mg twice daily for up to 30 days.
Brilinta carries a boxed warning for serious and sometimes fatal bleeding. It is contraindicated with active pathological bleeding or a history of intracranial hemorrhage. Other concerns include shortness of breath, ventricular pauses and other slow heart rhythms, central sleep apnea, and rare thrombotic thrombocytopenic purpura. Severe liver impairment is a reason to avoid treatment.
Yes. Ticagrelor blocks platelet P2Y12 receptors and reduces platelet activation and aggregation.
Maintenance treatment is taken twice daily. The tablet strength and treatment duration depend on the cardiovascular or cerebrovascular indication.
Yes. The boxed warning covers serious and sometimes fatal bleeding.
Yes. Dyspnea is a recognized adverse reaction and can lead to treatment discontinuation when it becomes intolerable.
Antiplatelet Medications. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK537062/. Date Accessed September 16, 2026.
BRILINTA (ticagrelor) Prescribing Information. AstraZeneca Medical Information. https://medicalinformation.astrazeneca-us.com/home/prescribing-information/brilinta.html. Date Accessed September 16, 2026.
DailyMed - BRILINTA (ticagrelor) tablet. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8. Date Accessed September 16, 2026.
FDA Label - BRILINTA (ticagrelor) Tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022433s039lbl.pdf. Date Accessed September 16, 2026.
Ticagrelor. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a611050.html. Date Accessed September 16, 2026.